Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

towa pharmaceutical co., ltd. - betaxolol hydrochloride - white tablet with split line, diameter: 7.1 mm, thickness: 3.2 mm

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

towa pharmaceutical co., ltd. - betaxolol hydrochloride - white tablet with split line, diameter: 5.6 mm, thickness: 2.5mm

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

sawai pharmaceutical co.,ltd. - betaxolol hydrochloride - white tablet, diameter: 7.1 mm, thickness: 3.3 mm

Japan - English - すりの適正使用協議会 RAD-AR Council, Japan

sawai pharmaceutical co.,ltd. - betaxolol hydrochloride - white tablet, diameter: 6.1 mm, thickness: 3.2 mm

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - betaxolol hydrochloride -

New Zealand - English - Medsafe (Medicines Safety Authority)

rex medical ltd - betaxolol hydrochloride 0.56%{relative} equivalent to betaxolol 0.5% - eye drops, solution - 0.5% w/v - active: betaxolol hydrochloride 0.56%{relative} equivalent to betaxolol 0.5% excipient: benzalkonium chloride disodium edetate dihydrate sodium chloride sodium hydroxide water for injection - betaxolol hydrochloride 0.5% w/v eye drops have been shown to be effective in lowering intraocular pressure and are indicated in the treatment of ocular hypertension or chronic open angle glaucoma. betaxolol 0.5% w/v eye drops may be used alone or in combination with other iop-lowering medication.

United States - English - NLM (National Library of Medicine)

alcon laboratories, inc. - betaxolol hydrochloride (unii: 6x97d2xt0o) (betaxolol - unii:o0zr1r6rz2) - kit - betoptic® pilo ophthalmic suspension is indicated for the reduction of elevated intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension who are insufficiently responsive to betoptic® -s (failed to achieve target iop determined after multiple measurements over time). it is not known whether betoptic® pilo is equivalent in iop lowering efficacy to the administration of betoptic® -s 0.25% and pilocarpine 1.75% dosed separately. it is not known whether betoptic® pilo is equivalent to other beta-blockers given in combination with pilocarpine. betoptic® pilo ophthalmic suspension is contraindicated in patients with sinus bradycardia, greater than a first degree atrioventricular heart block, cardiogenic shock or patients with overt cardiac failure. betoptic® pilo ophthalmic suspension is also contraindicated in conditions where miosis is undesirable (e.g., peripheral anterior synechia, trauma, acute inflammatory disease of the anterior chamber, glaucoma occurring or persisting

United States - English - NLM (National Library of Medicine)

alcon - betaxolol hydrochloride (unii: 6x97d2xt0o) (betaxolol - unii:o0zr1r6rz2) - solution/ drops - 5.6 mg in 1 ml - betoptic ophthalmic solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of ocular hypertension and chronic open-angle glaucoma. it may be used alone or in combination with other anti-glaucoma drugs. in clinical studies betoptic was safely used to lower intraocular pressure in 47 patients with both glaucoma and reactive airway disease who were followed for a mean period of 15 months. however, caution should be used in treating patients with severe reactive airway disease or a history of asthma. hypersensitivity to any component of this product. betoptic ophthalmic solution is contraindicated in patients with sinus bradycardia, greater than a first degree atrioventricular block, cardiogenic shock, or patients with overt cardiac failure.

United States - English - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - betaxolol hydrochloride (unii: 6x97d2xt0o) (betaxolol - unii:o0zr1r6rz2) - betoptic s® (betaxolol hydrochloride ophthalmic suspension) 0.25% is indicated for the treatment of elevated intraocular pressure (iop) in patients with chronic open-angle glaucoma or ocular hypertension. betoptic s is contraindicated in patients with: - sinus bradycardia - greater than a first degree atrioventricular (av) block - cardiogenic shock - patients with overt cardiac failure - hypersensitivity to any component of this product risk summary there are no adequate and well-controlled studies of betoptic s administration in pregnant women to inform a drug-associated risk. there are limited data with the use of betaxolol eye drops in pregnant women. epidemiological studies have not revealed malformative effects but show a risk for intrauterine growth retardation when beta-blockers are administered by the oral route. in animal reproductive studies, no drug-induced maternal toxicity or teratogenicity was observed at clinically relevant doses (see data) . because animal reproductive studies are not always

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - betaxolol hydrochloride 5.6 mg/ml equivalent to 0.5% betaxolol base - eye drops, solution - 0.5% w/v - active: betaxolol hydrochloride 5.6 mg/ml equivalent to 0.5% betaxolol base excipient: benzalkonium chloride disodium edetate dihydrate hydrochloric acid sodium chloride sodium hydroxide water for injection